Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

How does real-world evidence inform decision making for new drug funding?

The limitations of clinical evidence from trials when data presented for HTA: Immature survival data, selected patient populations, phase II data for uncommon cancers etc...

Date

16 Sep 2021

Session

How does real-world evidence inform decision making for new drug funding?

Topics

Clinical Research;  Targeted Therapy

Tumour Site

Presenters

Nathan Cherny

Authors

N.I. Cherny

Author affiliations

  • Oncology Institute, Shaare Zedek Medical Center, 9103102 - Jerusalem/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.